Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Paul Keck

Psychiatry Cincinnati, OH Medical Doctor

NPI 1710062872 CMS profile 31814

231 Albert Sabin Way, Mail Location 0559, Cincinnati, OH 45267

Open in the dashboard

General payments

$738,524

676 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Paul Keck of Cincinnati, OH is reported in the CMS Open Payments database as having received $738,524 across 676 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $182,123 172
2024 General $112,032 105
2023 General $170,795 156
2022 General $163,239 138
2021 General $25,025 29
2020 General $60,730 48
2019 General $24,579 28

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Paul Keck
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Paul Keck were reported at $182,123. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Paul Keck Psychiatry median Middle half National median
2019 $24,579 $184 $59–$605 $163
2020 $60,730 $119 $36–$372 $114
2021 $25,025 $143 $43–$576 $132
2022 $163,239 $153 $50–$590 $149
2023 $170,795 $170 $56–$651 $160
2024 $112,032 $179 $57–$673 $164
2025 $182,123 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Axsome Therapeutics, Inc. $186,709 170 payments
  2. Teva Pharmaceuticals USA, Inc. $114,199 78 payments
  3. Alkermes, Inc. $112,330 114 payments
  4. AbbVie, Inc. $105,356 102 payments
  5. ITI, Inc. $77,707 72 payments
  6. Allergan Inc. $75,327 71 payments
  7. Otsuka America Pharmaceutical, Inc. $27,945 32 payments
  8. Eli Lilly and Company $11,585 5 payments
  9. Merck Sharp & Dohme Corporation $10,783 11 payments
  10. Vanda Pharmaceuticals Inc. $8,569 14 payments
  11. Other $8,015 7 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $464,548 168 payments
  2. Consulting Fee $176,549 61 payments
  3. Honoraria $53,802 15 payments
  4. Travel and Lodging $27,207 224 payments
  5. Food and Beverage $11,291 201 payments
  6. Compensation for serving as faculty or as a speaker for a medical education program $5,000 1 payment
  7. Education $127 6 payments
Products named General payments · program years 2019–2025
  1. Auvelity $186,709 170 payments
  2. LYBALVI Cns $109,960 113 payments
  3. LYBALVI Cns $109,923 112 payments
  4. LYBALVI Cns $109,823 111 payments
  5. LYBALVI Cns $109,823 111 payments
  6. VRAYLAR Neuroscience $98,508 89 payments
  7. CAPLYTA $77,707 72 payments
  8. AUSTEDO $76,108 51 payments
  9. VRAYLAR Neuroscience $71,549 65 payments
  10. Austedo XR $36,382 26 payments
  11. Other $45,864 61 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

202

Median for Psychiatry & Neurology: 100

Drug cost

$27,833

Median for Psychiatry & Neurology: $2,986

Branded share of claims

19.3%

Median for Psychiatry & Neurology: 16.2%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Auvelity Dextromethorphan Hbr/Bupropion Brand 15 $21,499
Aripiprazole Generic 16 $2,955
Quetiapine Fumarate Generic 14 $704
Mirtazapine Generic 18 $676
Bupropion Hcl Sr Bupropion Hcl Brand 24 $510
Gabapentin Generic 20 $369
Trazodone Hcl Generic 30 $284
Escitalopram Oxalate Generic 13 $257
Lamotrigine Generic 21 $221
Clonazepam Generic 18 $192

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,755 Part D prescribers listed as Psychiatry & Neurology; they describe a distribution and say nothing about conduct.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Auvelity
  • Axsome Therapeutics, Inc. $55,146
$55,146 15 —
VRAYLAR
  • AbbVie, Inc. $27,756
$27,756 — —
Austedo XR
  • Teva Pharmaceuticals USA, Inc. $19,559
$19,559 — —
LYBALVI
  • Alkermes, Inc. $7,648
$7,648 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

676 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record